» Articles » PMID: 34987851

Bilateral Renal Infarction with COVID-19 Pneumonia: a Case Report

Overview
Specialty General Medicine
Date 2022 Jan 6
PMID 34987851
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Acute renal infarction is a rare and often underdiagnosed condition with estimated incidence of 0.5-1.5%. Coronavirus disease 2019 (COVID-19) has been shown to cause a hypercoagulable state in patients leading to arterial and venous thromboembolism. Renal infarction as a consequence of COVID-associated coagulopathy has been reported, sometimes resulting in acute kidney injury. Most of the patients so far reported had other existing comorbidities and risk factors that compounded the risk of precipitating an infarction. Here, we present a 37-year-old, the youngest patient reported so far, with no pre-existing comorbidities or risk factors, who developed bilateral renal infarction with COVID-19 pneumonia. The patient was treated with anticoagulation for renal infarction and discharged on apixaban. Anticoagulation is an important part of current treatment strategies for COVID-19 pneumonia and should extend beyond the acute phase of the disease to prevent long-term sequelae, especially in young patients.

Citing Articles

A Pictorial Essay Describing the CT Imaging Features of COVID-19 Cases throughout the Pandemic with a Special Focus on Lung Manifestations and Extrapulmonary Vascular Abdominal Complications.

Brogna B, Bignardi E, Megliola A, Laporta A, La Rocca A, Volpe M Biomedicines. 2023; 11(8).

PMID: 37626610 PMC: 10452395. DOI: 10.3390/biomedicines11082113.


Acute Renal Vein Thrombosis Following COVID-19 in a Lupus Patient: A Case Report and Review of the Literature.

Petrou D, Sardeli A, Vlachoyiannopoulos P, Moschovaki-Zeiger O, Lionaki S Life (Basel). 2023; 13(6).

PMID: 37374035 PMC: 10305519. DOI: 10.3390/life13061252.


Comparison of Two Waves of COVID-19 in Critically Ill Patients: A Retrospective Observational Study.

Jana K, Yap E, Janga K, Greenberg S Int J Nephrol. 2022; 2022:3773625.

PMID: 35665075 PMC: 9161135. DOI: 10.1155/2022/3773625.

References
1.
Cuker A, Tseng E, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K . American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021; 5(3):872-888. PMC: 7869684. DOI: 10.1182/bloodadvances.2020003763. View

2.
Connors J, Levy J . COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020; 135(23):2033-2040. PMC: 7273827. DOI: 10.1182/blood.2020006000. View

3.
Su H, Yang M, Wan C, Yi L, Tang F, Zhu H . Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020; 98(1):219-227. PMC: 7194105. DOI: 10.1016/j.kint.2020.04.003. View

4.
Salabei J, Fishman T, Asnake Z, Ali A, Iyer U . COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. Heart Lung. 2021; 50(2):357-360. PMC: 7816593. DOI: 10.1016/j.hrtlng.2021.01.011. View

5.
Connell N, Battinelli E, Connors J . Coagulopathy of COVID-19 and antiphospholipid antibodies. J Thromb Haemost. 2020; 18(9):E1-E2. PMC: 7267637. DOI: 10.1111/jth.14893. View